Abstract
High-grade gliomas include malignant variants of tumors derived from astrocytic and oligodendropheral cell lines. These tumors demonstrate invasive behavior, are rapidly growing and are usually characterized by contrast enhancement and edema on MR or CT neuroimaging. Management includes either biopsy or surgical resection followed by radiotherapy in the majority of cases. Additional adjuvant chemotherapy is also a treatment consideration. Despite advances in management, the prognosis remains poor, with few patients surviving beyond 2–3 years.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Legler JM, Ries LA, Smith MA, Warren JL, Heineman EF, Kaplan RS et al. Cancer surveillance series (corrected): brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 1999;91(16):1382–90.
Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61(3):215–25;discussion:226–9.
Kleihues, P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol 1999;1(1):44–51.
Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999;155(2):375–86.
Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR et al. Survival and failure patterns of highgrade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002;20(6):1635–42.
Halligan JB, Stelzer KJ, Rostomily RC, Spence AM, Griffin TW, Berger MS et al. Operation and permanent low activity 125I brachytherapy for recurrent highgrade astrocytomas. Int J Radiat Oncol Biol Phys 1996;35(3):541–7.
Scherer HJ. Structural development in gliomas. Am J Cancer 1938;34(3):333–51.
Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987;66(6):865–74.
Silbergeld DL, Chicoine MR. Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 1997;86(3):525–31.
Ojemann JG, Miller JW, Silbergeld DL. Preserved function in brain invaded by tumor. Neurosurgery 1996;39(2):253–8;discussion:258–9.
Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W et al. From the cover: neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000;97(23):12846–51.
Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85(9):704–10.
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17(8):2572.
Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS et al. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 1994;35(3):378–88;discussion:388.
Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7(4):839–45.
Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49(3):333–43.
Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359(9311):1011–18.
Duong DH, Rostomily RC, Haynor DR, Keles GE, Berger MS. Measurement of tumor resection volumes from computerized images. Technical note. J Neurosurg 1992;77(1):151–4.
Henegar MM, Moran CJ, Silbergeld DL. Early post-operative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg 1996;84(2):174–9.
Keles GE, Anderson B, and Berger MS. The effect of sextent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 1999;52(4):371–9.
Silbergeld DL, Rostomily RC. Resection of glioblastoma. J Neurosurg 2002;96(4):809;discussion:810.
Barker FG Jr, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998;42(4):709–20; discussion:720–3.
Alvord EC Jr. Simple model of recurrent gliomas. J Neurosurg 1991;75(2):337–8.
Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T. Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol 2001;52(2):161–71.
Domino KB, Hemstad JR, Lam AM, Laohaprasit V, Mayberg TA, Harrison SD et al. Effect of nitrous oxide on intracranial pressure after cranial-dural closure in patients undergoing craniotomy. Anesthesiology 1992;77(3):421–5.
Field M, Witham TF, Flickinger JC, Kondziolka D, Lunsford LD. Comprehensive assessment of hemorrhage risks and outcomes after stereotactic brain biopsy. J Neurosurg 2001;94(4):545–51.
Silbergeld DL. Cortical mapping. In: Luders HO and Comair YG, editors. Epilepsy surgery. Philadelphia: Lippincott Williams & Wilkins, 2002; 633–5.
Silbergeld DL, Miller JW. Intraoperative cerebral mapping and monitoring. Contemp Neurosurg 1996;18(11):1–6.
Silbergeld DL, Ojemann GA. The tailored temporal lobectomy. Neurosurg Clin N Am 1993;4(2):273–81.
Ojemann G, Ojemann J, Lettich E, Berger M. Cortical language localization in left, dominant hemisphere. An electrical stimulation mapping investigation in 117 patients. J Neurosurg 1989;71(3):316–26.
Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345(8956):1008–12.
Westphal M, Hilt D, Bortey E, Delavault P, Olivares R, Warnke P et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003;5(2):79–88.
Florell RC, Macdonald DR, Irish WD, Bernstein M, Leibel SA, Gutin PH et al. Selection bias, survival, and brachytherapy for glioma. J Neurosurg 1992;76(2):179–83.
Broaddus WC, Gillies GT, Kucharczyk J. Minimally invasive procedures. Advances in image-guided delivery of drug and cell therapies into the central nervous system. Neuroimaging Clin N Am 2001;11(4):727–35.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag London Limited
About this chapter
Cite this chapter
Rostomily, R.C., Spence, A.M., Silbergeld, D.L. (2005). Neurosurgical Management of High-grade Gliomas. In: Moore, A.J., Newell, D.W. (eds) Neurosurgery. Springer Specialist Surgery Series. Springer, London. https://doi.org/10.1007/1-84628-051-6_10
Download citation
DOI: https://doi.org/10.1007/1-84628-051-6_10
Publisher Name: Springer, London
Print ISBN: 978-1-85233-522-9
Online ISBN: 978-1-84628-051-1
eBook Packages: MedicineMedicine (R0)